{"paper_id":"698beaf9-47f9-4e17-b85f-74a9b3e3d183","body_text":"Abstract\nThe corpus luteum of women is remarkable. The dominant follicle shows high levels of cellular proliferation, and its transition into the corpus luteum involves intense angiogenesis, higher than that seen in the most aggressive solid tumors. The corpus luteum, however, does not undergo malignant change. Its formation and resolution involve acute inflammatory responses and yet these processes are completed with no evidence of scarring. It is the most active endocrine gland in the body with a huge capacity for steroid synthesis, making up to 40 mg progesterone each day, and there are no disorders of clinical function. It has an essential role in human reproduction and the establishment of pregnancy, and yet we still do not fully understand how it works at a molecular level. The corpus luteum is fundamental to women’s health but research into the human corpus luteum is decreasing. However, although increased molecular understanding of the corpus luteum in women may facilitate the development of novel contraceptive paradigms and strategies to reduce the incidence and impact of ovarian hyperstimulation syndrome in assisted conception, it is likely that understanding the corpus luteum will provide generic insights into processes that affect the health of men and women throughout and beyond their reproductive years.\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nDuncan WC. The human corpus luteum: remodelling during luteolysis and maternal recognition of pregnancy. Rev Reprod. 2000;5:12–7.\nDevoto L, Fuentes A, Kohen P, Céspedes P, Palomino A, Pommer R, Muñoz A, Strauss III JF. The human corpus luteum: life cycle and function in natural cycles. Fertil Steril. 2009;92:1067–79.\nCsapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence. Obstet Gynecol Surv. 1978;33:69–81.\nDunlop CE, Anderson RA. The regulation and assessment of follicular growth. Scand J Clin Lab Invest Suppl. 2014;244:13–7.\nDonnez J, Squifflet J, Jadoul P, Demylle D, Cheron AC, Van Langendonckt A, Dolmans MM. Pregnancy and live birth after autotransplantation of frozen-thawed ovarian tissue in a patient with metastatic disease undergoing chemotherapy and hematopoietic stem cell transplantation. Fertil Steril. 1787;2011(95):e1–4.\nJabbour HN, Kelly RW, Fraser HM, Critchley HO. Endocrine regulation of menstruation. Endocr Rev. 2006;27:17–46.\nGroome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 1996;81:1401–5.\nStouffer RL, Xu F, Duffy DM. Molecular control of ovulation and luteinization in the primate follicle. Front Biosci. 2007;12:297–307.\nRichards JS, Russell DL, Ochsner S, Espey LL. Ovulation: new dimensions and new regulators of the inflammatory-like response. Ann Rev Physiol. 2002;64:69–92.\nBrezinka C. 3D ultrasound imaging of the human corpus luteum. Reprod Biol. 2014;14:110–4.\nParsons AK. Imaging the human corpus luteum. J Ultrasound Med. 2001;20:811–9.\nJokubkiene L, Sladkevicius P, Rovas L, Valentin L. Assessment of changes in volume and vascularity of the ovaries during the normal menstrual cycle using three dimensional power Doppler ultrasound. Hum Reprod. 2006;21:2661–8.\nTamura H, Takasaki A, Taniguchi K, Matsuoka A, Shimamura K, Sugino N. Changes in blood-flow impedance of the human corpus luteum throughout the luteal phase and during early pregnancy. Fertil Steril. 2008;90:2334–9.\nZeleznik AJ. In vivo responses of the primate corpus luteum to luteinizing hormone and chorionic gonadotropin. Proc Natl Acad Sci USA. 1998;95:11002–7.\nDuncan WC, Myers M, Dickinson RE, van den Driesche S, Fraser HM. Luteal development and luteolysis in the primate corpus luteum. Anim Reprod. 2009;6:34–46.\nSivalingam VN, Duncan WC, Kirk E, Shephard LA, Horne AW. Diagnosis and management of ectopic pregnancy. J Fam Plann Reprod Health Care. 2011;37:231–40.\nJärvelä IY, Ruokonen A, Tekay A. Effect of rising hCG levels on the human corpus luteum during early pregnancy. Hum Reprod. 2008;23:2775–81.\nTay PYS, Lenton EA. The optimum time for exogenous human chorionic gonadotropin to rescue the corpus luteum. J Assisted Reprod Genet. 1999;16:495–9.\nIllingworth PJ, Reddi K, Smith K, Baird DT. Pharmacological ‘rescue’ of the corpus luteum results in increased inhibin production. Clin Endocrinol (Oxf). 1990;33:323–32.\nCasper RF. Basic understanding of gonadotropin-releasing hormone-agonist triggering. Fertil Steril. 2015;103:867–9.\nLunn SF, Fraser HM, Mason HD. Structure of the corpus luteum in the ovulatory polycystic ovary. Hum Reprod. 2002;17:111–7.\nNishimori K, Dunkel L, Hsueh AJ, Yamoto M, Nakano R. Expression of luteinizing hormone and chorionic gonadotropin receptor messenger ribonucleic acid in human corpora lutea during menstrual cycle and pregnancy. J Clin Endocrinol Metab. 1995;80:1444–8.\nMiceli F, Minici F, Garcia Pardo M, Navarra P, Proto C, Mancuso S, Lanzone A, Apa R. Endothelins enhance prostaglandin (PGE(2) and PGF(2alpha)) biosynthesis and release by human luteal cells: evidence of a new paracrine/autocrine regulation of luteal function. J Clin Endocrinol Metab. 2001;86:811–7.\nAuletta FJ, Flint AP. Mechanisms controlling corpus luteum function in sheep, cows, nonhuman primates, and women especially in relation to the time of luteolysis. Endocr Rev. 1988;9:88–105.\nStocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, function, and regression. Endocr Rev. 2007;28:117–49.\nPeegel H, Randolph Jr J, Midgely AR, Menon KMJ. In situ hybridization of luteinizing hormone/human chorionic gonadotropin receptor messenger ribonucleic acid during hormone-induced down-regulation and the subsequent recovery in rat corpus luteum. Endocrinology. 1994;135:1044–51.\nDuncan WC, McNeilly AS, Fraser HM, Illingworth PJ. Luteinizing hormone receptor in the human corpus luteum: lack of down regulation during maternal recognition of pregnancy. Hum Reprod. 1996;11:2291–7.\nFraser HM, Duncan WC. Regulation and manipulation of angiogenesis in the ovary and endometrium. Reprod Fertil Dev. 2009;21:277–392.\nStouffer RL, Bishop CV, Bogan RL, Xu F, Hennebold JD. Endocrine and local control of the primate corpus luteum. Reprod Biol. 2013;13:259–71.\nMyers M, Gay E, McNeilly AS, Fraser HM, Duncan WC. In vitro evidence suggests activin-A may promote tissue remodeling associated with human luteolysis. Endocrinology. 2007;148:3730–9.\nChin KV, Seifer DB, Feng B, Lin Y, Shih WC. DNA microarray analysis of the expression profiles of luteinized granulosa cells as a function of ovarian reserve. Fertil Steril. 2002;77:1214–8.\nDuncan WC, Gay E, Maybin JA. The effect of luteal rescue with human chorionic gonadotrophin (hCG) on human luteal-cell progesterone receptors. Reproduction. 2005;130:83–93.\nRodewald M, Herr D, Duncan WC, Fraser HM, Hack G, Konrad R, Gagsteiger F, Kreienberh R, Wulff C. Molecular mechanisms of ovarian hyperstimulation syndrone: paracrine reduction of endothelial Claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod. 2009;24:1191–9.\nDuncan WC, Hillier SG, Gay E, Bell J, Fraser HM. Connective tissue growth factor (CTGF) expression in the human corpus luteum: paracrine regulation by human chorionic gonadotropin (hCG). J Clin Endocrinol Metab. 2005;90:5366–76.\nDuncan WC, Illingworth PJ, Young FM, Fraser HM. Induced luteolysis in the primate: rapid loss of luteinising hormone (LH) receptors. Hum Reprod. 1998;13:2532–40.\nHutchison JS, Nelson PB, Zeleznik AJ. Effects of different gonadotropin pulse frequencies on corpus luteum function during the menstrual cycle of rhesus monkeys. Endocrinology. 1986;119:1964–71.\nDuncan WC, Cowen GM, Illingworth PJ. Steroidogenic enzyme expression in human corpora lutea in the absence and presence of exogenous human chorionic gonadotrophin. Mol Hum Reprod. 1999;5:291–8.\nDuncan WC, Rodger FE, Illingworth PJ. The human corpus luteum: reduction in macrophages during maternal recognition of pregnancy. Hum Reprod. 1998;13:2435–42.\nNio-Kobayashi J, Trendell J, Giakoumelou S, Boswell L, Nicol L, Kudo M, Sakuragi N, Iwanaga T, Duncan WC. Bone morphogenetic proteins are mediators of luteolysis in the human corpus luteum. Endocrinology. 2015;156:1494–503.\nNio-Kobayashi J, Boswell L, Amano M, Iwanaga T, Duncan WC. The loss of luteal progesterone production in women is associated with a galectin switch via α2,6-sialylation of glycoconjugates. J Clin Endocrinol Metab. 2014;99:4616–24.\nDuncan WC, McNeilly AS, Illingworth PJ. The effect of luteal ‘rescue’ on the expression and localization of matrix metalloproteinases and their tissue inhibitors in the human corpus luteum. J Clin Endocrinol Metab. 1998;83:2470–8.\nWulff C, Wilson H, Largue P, Duncan WC, Armstrong DG, Fraser HM. Angiogenesis in the human corpus luteum: localization and changes in angiopoietins, Tie-2, and vascular endothelial growth factor messenger ribonucleic acid. J Clin Endocrinol Metab. 2000;85:4302–9.\nFraser HM, Lunn SF. Regulation and manipulation of angiogenesis in the primate corpus luteum. Reproduction. 2001;121:355–62.\nBishop CV, Molskness TA, Xu F, Belcik JT, Lindner JR, Slayden OD, Stouffer RL. Quantification of dynamic changes to blood volume and vascular flow in the primate corpus luteum during the menstrual cycle. J Med Primatol. 2014;43:445–54.\nvan den Driesche S, Myers M, Gay E, Thong KJ, Duncan WC. Human chorionic gonadotrophin up-regulates hypoxia inducible factor-1 alpha in luteinised granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum. Mol Hum Reprod. 2008;14:455–64.\nFraser HM, Bell J, Wilson H, Taylor PD, Morgan K, Anderson RA, Duncan WC. Localization and quantification of cyclic changes in the expression of endocrine gland vascular endothelial growth factor in the human corpus luteum. J Clin Endocrinol Metab. 2005;90:427–34.\nFraser HM, Wilson H, Wulff C, Rudge JS, Wiegand SJ. Administration of vascular endothelial growth factor Trap during the post-angiogenic period of the luteal phase causes rapid functional luteolysis and selective endothelial cell death in the marmoset. Reproduction. 2006;132:589–600.\nWulff C, Dickson SE, Duncan WC, Fraser HM. Angiogenesis in the human corpus luteum: simulated early pregnancy by HCG treatment is associated with both angiogenesis and vessel stabilization. Hum Reprod. 2001;16:2515–24.\nHerr D, Bekes I, Wulff C. Regulation of endothelial permeability in the corpus luteum: a review of the literature. Geburtshilfe Frauenheilkd. 2013;73:1107–11.\nGroten T, Fraser HM, Duncan WC, Konrad R, Kreienberg R, Wulff C. Cell junctional proteins in the human corpus luteum: changes during the normal cycle and after HCG treatment. Hum Reprod. 2006;21:3096–102.\nRodewald M, Herr D, Fraser HM, Hack G, Kreienberg R, Wulff C. Regulation of tight junction proteins occludin and claudin 5 in the primate ovary during the ovulatory cycle and after inhibition of vascular endothelial growth factor. Mol Hum Reprod. 2007;13:781–9.\nMacklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170–207.\nSampaio M, Serra V, Miro F, Calatayud C, Castellvi RM, Pellicer A. Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration. Hum Reprod. 1991;6:194–7.\nUrbancsek J, Witthaus E. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization. Fertil Steril. 1996;65:966–71.\nDepalo R, Jayakrishan K, Garruti G, Totaro I, Panzarino M, Giorgino F, Selvaggi LE. GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET). Reprod Biol Endocrinol. 2012;10:26.\nFraser HM, Sandow J. Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey. J Clin Endocrinol Metab. 1985;60:579–84.\nMurphy BD. Models of luteinization. Biol Reprod. 2000;63:2–11.\nLiu L, Kong N, Xia G, Zhang M. Molecular control of oocyte meiotic arrest and resumption. Reprod Fertil Dev. 2013;25:463–71.\nWang W, Zhang X-H, Wang W-H, Liu Y-L, Zhao L-H, Xue S-L, Yang K-H. The time interval between hCG priming and oocyte retrieval in ART program: a meta-analysis. J Assist Reprod Genet. 2011;28:901–10.\nPriddy AR, Killick SR. Eicosanoids and ovulation. Prostaglandins Leukot Essent Fatty Acids. 1993;49:827–31.\nMicu MC, Micu R, Ostensen M. Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies. Arthritis Care Res. 2011;63:1334–8\nDuffy DM, Stouffer RL. Follicular administration of a cyclooxygenase inhibitor can prevent oocyte release without alteration of normal luteal function in rhesus monkeys. Hum Reprod. 2002;17:2825–31.\nKasum M, Danolić D, Orešković S, Ježek D, Beketić-Orešković L, Pekez M. Thrombosis following ovarian hyperstimulation syndrome. Gynecol Endocrinol. 2014;30:764–8.\nSmith V, Osianlis T, Vollenhoven B. Prevention of ovarian hyperstimulation syndrome: a review. Obstet Gynecol Int. 2015;2015:514159.\nFiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. Reprod Biol Endocrinol. 2012;10:32.\nDuncan WC, Nio-Kobayashi J. Targeting angiogenesis in the pathological ovary. Reprod Fertil Dev. 2013;25:362–71.\nDuncan WC. A guide to understanding polycystic ovary syndrome (PCOS). J Fam Plann Reprod Health Care. 2014;40:217–25.\nPalomba S, Falbo A, Carrillo L, Villani MT, Orio F, Russo T, Di Cello A, Cappiello F, Capasso S, Tolino A, Colao A, Mastrantonio P, La Sala GB, Zullo F, Cittadini E; METformin in High Responder Italian Group. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Fertil Steril. 2011;96:1384–90.e4.\nYoussef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, van der Veen F. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010;16:459–66.\nJayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Sridharan M, Mason AJ, Warwick J, Ashby D, Ghatei MA, Bloom SR, Carby A, Trew GH, Dhillo WS. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124:3667–77.\nDjahanbakhch O, Swanton IA, Corrie JE, McNeilly AS. Prediction of ovulation by progesterone. Lancet. 1981;2:1164–5.\nEcochard R, Duterque O, Leiva R, Bouchard T, Vigil P. Self-identification of the clinical fertile window and the ovulation period. Fertil Steril. 2015;103:1319–25.e3.\nHaggerty CL, Ness RB, Kelsey S, Waterer GW. The impact of estrogen and progesterone on asthma. Ann Allergy Asthma Immunol. 2003;90:284–91.\nBrisken C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer. 2013;13:385–96.\nImai A, Ichigo S, Matsunami K, Takagi H. Premenstrual syndrome: management and pathophysiology. Clin Exp Obstet Gynecol. 2015;42:123–8.\nShivapathasundram G, Kwik M, Chapman M. Luteal phase defect: part of the infertility zeitgeist or relic from the past? Hum Fertil. 2011;14:60–3.\nMcNeilly AS, Howie PW, Houston MJ, Cook A, Boyle H. Fertility after childbirth: adequacy of post-partum luteal phases. Clin Endocrinol (Oxf). 1982;17:609–15.\nThe ESHRE Capri Workshop Group. Anovulatory infertility. Hum Reprod. 1995;10:1549–53.\nBaerwalda R, Adams GP, Pierson RA. Form and function of the corpus luteum during the human menstrual cycle. Ultrasound Obstet Gynecol. 2005;25:498–507.\nHamilton MP, Fleming R, Coutts JR, Macnaughton MC, Whitfield CR. Luteal cysts and unexplained infertility: biochemical and ultrasonic evaluation. Fertil Steril. 1990;54:32–7.\nPerkins KY, Johnson JL, Kay HH. Simple ovarian cysts. Clinical features on a first-trimester ultrasound scan. J Reprod Med. 1997;42:440–4.\nVercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Fedele L. ‘Blood on the tracks’ from corpora lutea to endometriomas. BJOG. 2009;116:366–71.\nFiaschette V, Ricci A, Lia Scarano A, Liberto V, Citraro D, Arduini S, Sorrenti G, Simonette G. Haemoperitoneum from corpus luteal cyst rupture: a practical approach in the emergency room. Case Rep Emerg Med. 2014;2014:252657.\nArulpragasam K, Atkinson A, Epee-Bekima M. An unexpected presentation of haemoperitoneum in a pregnant women. Case Rep Obstet Gynecol. 2015;2015:169582.\nChetty M, Duncan WC. Investigation and management of recurrent miscarriage. Obstet Gynecol Reprod Med. 2015;25:31–6.\nSzekeres-Bartho J, Balasch J. Progestogen therapy for recurrent miscarriage. Hum Reprod Update. 2008;14:27–35.\nCoomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373:2141–8.\nDante G, Vaccaro V. Facchinetti F. Use of progesterone during early pregnancy. Facts Views Vis Obgyn. 2013;5:66–71.\nHaas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev. 2013;10, CD003511.\nCarmichael SL, Shaw GM, Laurent C, Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med. 2005;159:957–62.\nKutlusoy F, Guler I, Erdem M, Erdem A, Bozkurt N, Biberoglu EH, Biberoglu KO. Luteal phase support with estrogen in addition to progesterone increases pregnancy rates in in vitro fertilization cycles with poor response to gonadotropins. Gynecol Endocrinol. 2014;30:363–6.\nWang Y-C, Su H-Y, Liu J-Y, Chang F-W, Chen C-H. Maternal and female virilization caused by pregnancy luteomas. Fertil Steril. 2005;84:509.\nIllingworth PJ, Johnstone FD, Steel J, Seth J. Luteoma of pregnancy: masculinisation of a female fetus prevented by placental aromatisation. Br J Obstet Gynaecol. 1992;99:1019–20.\nvan der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7, CD009154.\nConnell MT, Szatkowski JM, Terry N, DeCherney AH, Propst AM, Hill MJ. Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril. 2015;103:939–46.\nLiu X-R, Mu H-Q, Shi Q, Xiao X-Q, Qi H-B. The optimal duration of progesterone supplementation in pregnant women after IVF/ICSI: a meta-analysis. Reprod Biol Endocrinol. 2012;10:107.\nRussell R, Kingsland C, Alfirevic Z, Gazvani R. Duration of luteal support after IVF is important, so why is there no consistency in practice? The results of a dynamic survey of practice in the United Kingdom. Hum Fertil (Camb). 2015;18:43–7.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2017 Springer International Publishing Switzerland\nAbout this chapter\nCite this chapter\nDuncan, W.C. (2017). The Corpus Luteum and Women’s Health. In: Meidan, R. (eds) The Life Cycle of the Corpus Luteum. Springer, Cham. https://doi.org/10.1007/978-3-319-43238-0_13\nDownload citation\nDOI: https://doi.org/10.1007/978-3-319-43238-0_13\nPublished:\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-319-43236-6\nOnline ISBN: 978-3-319-43238-0\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}